JP2004107268A - Carbonylation inhibiting agent for protein, skin care preparation for external use, and method - Google Patents

Carbonylation inhibiting agent for protein, skin care preparation for external use, and method Download PDF

Info

Publication number
JP2004107268A
JP2004107268A JP2002272826A JP2002272826A JP2004107268A JP 2004107268 A JP2004107268 A JP 2004107268A JP 2002272826 A JP2002272826 A JP 2002272826A JP 2002272826 A JP2002272826 A JP 2002272826A JP 2004107268 A JP2004107268 A JP 2004107268A
Authority
JP
Japan
Prior art keywords
skin
carbonylation
protein
edelweiss
external preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002272826A
Other languages
Japanese (ja)
Other versions
JP4608691B2 (en
Inventor
Tomonori Hata
畑 友紀
Yukiko Niimoto
新本 由紀子
Shizuka Uehara
上原 静香
Hiromoto Nakayama
中山 宏基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kose Corp
Pentapharm Japan Corp
Original Assignee
Kose Corp
Pentapharm Japan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kose Corp, Pentapharm Japan Corp filed Critical Kose Corp
Priority to JP2002272826A priority Critical patent/JP4608691B2/en
Publication of JP2004107268A publication Critical patent/JP2004107268A/en
Application granted granted Critical
Publication of JP4608691B2 publication Critical patent/JP4608691B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a carbonylation inhibiting agent capable of inhibiting carbonylation of a protein such as keratin, a skin care preparation for external use having enhancing effects on moisture-retaining properties of the skin, and to provide a method for achieving above effects. <P>SOLUTION: The carbonylation inhibiting agent for the protein comprises a component originating from Leontopodium alpinum as an effective ingredient. The skin care preparation for external use having enhancing effects on the moisture-retaining properties comprises the component originating from Leontopodium alpinum as an effective ingredient. The method for enhancing moisture-retaining properties of skin comprises supplying the component originating from Leontopodium alpinum. <P>COPYRIGHT: (C)2004,JPO

Description

【0001】
【発明が属する技術分野】
本発明は蛋白質、特に皮膚の角質細胞などを構成している蛋白質のカルボニル化を抑制するカルボニル化抑制剤、ならびにそれを用いた保湿性向上効果のある皮膚外用剤および方法に関する。
【0002】
【従来の技術】
皮膚の最表層は角質細胞からなり、その85%がケラチンから構成されている。ケラチンは、450〜500個のアミノ酸からなる繊維状の分子であり、基底層から角層へと分化するのに従い、細胞内で繊維化して角層の構造を形成する。近年、このケラチンが、日常的に皮膚が受ける酸化的ストレス(例えば、紫外線、タバコの煙)等によってカルボニル化されることが報告されている(例えば、非特許文献1参照)。しかし、角質細胞を構成するケラチンがカルボニル化されることによって、皮膚がどのようなダメージをうけるかについてはなんら報告がない。
【0003】
一方、従来、天然物由来の成分は、安全であることから、乳液、クリーム、化粧水、美容液、パック、洗浄料、分散液、軟膏、液剤、エアゾール剤、貼付剤、パップ剤、リニメント剤等の種々の皮膚外用剤に種々の薬効剤として添加されている。例えば、エーデルワイスの抽出物に美白効果があること(例えば、特許文献1参照)、およびエーデルワイスの抽出物が活性酸素消去剤として有効であること(例えば特許文献2参照)が報告されている。しかし、前記ケラチンのカルボニル化との関連については、なんら記載されていない。
【0004】
【非特許文献1】
Jens J. Thiele et al.; Protein Oxidation in Human Stratum Corneum: Susceptibility of Keratins to Oxidation In Vitro and Presence of a Keratin Oxidation Gradient In Vivo.; THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 113, No. 3, p.335,339(1999)
【特許文献1】
特開2002−138027号公報
【特許文献2】
特開2001−288032号公報
【0005】
【発明が解決しようとする課題】
本発明の課題は、蛋白質、特に角質細胞を構成するケラチン等の蛋白質のカルボニル化を抑制し得る蛋白質のカルボニル化抑制剤を提供することである。また、本発明の他の課題は、皮膚に対する安全性が良好であるとともに、皮膚の保湿性を高める効果を有する皮膚外用剤および方法を提供することである。
【0006】
【課題を解決するための手段】
本発明者らは、角質細胞を構成しているケラチンのカルボニル化について鋭意検討した結果、通常、ケラチンは水分子を多く取り込んでいるが、カルボニル化されることによって水分子を排除してしまい、カルボニル化された後のケラチンは水分子を取り込むことができないとの知見を得た。さらに、このことが皮膚を乾燥させ、皮膚の外観を損なうとの知見を得た。さらに、この知見に基いて検討を進めた結果、エーデルワイス由来の成分は、蛋白質のカルボニル化を抑制すること、および該成分を含有する皮膚外用剤は皮膚の保湿性を高める効果があることを見出し、本発明を完成するに至った。
【0007】
本発明の一態様として、エーデルワイス由来の成分を有効成分とする蛋白質のカルボニル化抑制剤が提供される。
また、本発明の他の態様として、エーデルワイス由来の成分を蛋白質のカルボニル化抑制剤として含有する皮膚外用剤;エーデルワイス由来の成分を有効成分として含有する保湿性皮膚外用剤;さらに紫外線防止剤を含有する前記皮膚外用剤;エーデルワイス由来の成分を供給することによって、蛋白質のカルボニル化を抑制する方法;エーデルワイス由来の成分を供給することによって、皮膚の保湿性を向上させる方法;が提供される。
【0008】
【発明の実施の形態】
本発明に用いられるエーデルワイス(Leontopodium alpinum)は、キク科のレオントポディウム属に属しており、ヨーロッパアルプスを象徴する植物として知られている。エーデルワイスは非常に稀な高山植物で、摘み取りが禁止されているため、従来、化粧品などの素材として入手することは非常に困難であった。本発明に用いられるエーデルワイスは正式な許可を得て入手し、栽培を行うことによって供給されたものである。本発明においては、エーデルワイスの産地等については特に限定されない。
【0009】
上記エーデルワイス由来の成分の調製については、特に限定されるものではないが、その例としては、全草、又は根、茎、幼芽、葉、花及び種子等のいずれか1以上の部位から、一般的な抽出方法を利用して調製することができる。より具体的には、これらを乾燥、細切、圧搾又は発酵等、適宜処理を施した後、低温もしくは室温〜加温下で溶媒中に浸漬し、抽出する方法を挙げることができる。抽出中には、溶媒を適宜攪拌してもよいし、また、溶媒を加温してもよい。用いる溶媒としては、例えば水、低級1価アルコール(メチルアルコール、エチルアルコール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール(グリセリン、プロピレングリコール、1,3−ブチレングリコール等)、低級アルキルエステル(酢酸エチル等)、炭化水素(ベンゼン、ヘキサン、ペンタン等)、ケトン類(アセトン、メチルエチルケトン等)、エーテル類(ジエチルエーテル、テトラヒドロフラン、ジプロピルエーテル等)、アセトニトリル等が挙げられ、1種又は2種以上を用いることができる。
【0010】
上記方法で得られた抽出物をそのまま、または、適宜の期間そのまま放置して熟成させた後に、蛋白質のカルボニル化抑制剤として種々の用途に供することができる。必要ならば、本発明の効果に影響のない範囲で、更に、濾過又はイオン交換樹脂等により、脱臭、脱色等の精製処理を施して用いることもできる。又、液体クロマトグラフィー等の分離手段を用い、活性の高い画分を取り出して用いることもできる。
【0011】
好ましい抽出方法の例としては、含水濃度0〜100vol%のエチルアルコール又は1,3−ブチレングリコール又はグリセリンを用い、室温で、又は加温して1〜5日間抽出を行ったのち濾過し、得られた濾液をさらに1週間ほど放置して熟成させ、再び濾過を行う方法が挙げられる。また、エーデルワイス由来の成分としては、「エーデルワイスGC」(ペンタファーム社製)が好適に用いられる。
【0012】
本発明の蛋白質のカルボニル化抑制剤は、エーデルワイス由来の成分を有効成分として含む限り、その形態については特に制限はない。液状、ペースト状、ゲル状等いずれの形態で用いることもできる。又は液状等の抽出物を、乾固させて固体状としたり、あるいはスプレードライ等により乾燥させて粉末として用いることもできる。
【0013】
エーデルワイス由来の成分は、蛋白質のカルボニル化抑制剤として機能する。本発明のカルボニル化抑制剤は、蛋白質の中でも特に角層、表皮及び真皮の構成蛋白質、より具体的には、ケラチン、コラーゲン及びエラスチンなどのカルボニル化を抑制する効果に優れる。また、酵素蛋白質のカルボニル化の抑制剤としても優れている。上記した様に、蛋白質、特に角質細胞を構成しているケラチンがカルボニル化されると、皮膚の保湿性が低下し、肌荒れや、皮膚のうるおい感、つや、はり等の低下など、皮膚の外観を損なう。本発明の蛋白質のカルボニル化抑制剤を皮膚外用剤に配合し、該皮膚外用剤を皮膚に適用することにより、蛋白質、特にケラチンがカルボニル化されるのを抑制し、その結果、皮膚の保湿性を向上させ、皮膚の外観を改善することができる。
なお、本明細書において「皮膚の保湿性向上効果」の用語は、実施例において行われる水分保持能試験によって直接確認できる効果の他、皮膚の乾燥による肌荒れ、並びに皮膚のうるおい感、つや及びはり等の低下などを予防あるいは改善する効果などを含めて最も広義に解釈するものとする。
【0014】
以下、本発明の蛋白質のカルボニル化抑制剤を含む皮膚外用剤について説明する。
本発明の皮膚外用剤は、前記カルボニル化抑制剤を含有することを特徴とする。本発明の皮膚外用剤における前記カルボニル化抑制剤、即ち、エーデルワイス由来の成分の含有量は、乾燥固形分として0.00001〜5質量%(以下単に「%」で示す)であるのが好ましく、0.0001〜2%であるのがより好ましい。この範囲内であれば、該成分を安定的に配合することができ、かつ高いカルボニル化抑制効果、さらにその効果に基づく保湿性向上効果を発揮することができる。また、抽出液を使用する場合は、溶質である乾燥固形分の含有量が上記範囲内であれば、その抽出液濃度は何ら限定されるものではない。
【0015】
本発明の好ましい実施の形態として、前記エーデルワイス由来の成分と、紫外線防止剤の一種又は二種以上とを含有する皮膚外用剤が挙げられる。
本実施の形態において、用いられる紫外線防止剤としては、パラメトキシケイ皮酸−2−エチルヘキシル、4−tert−ブチル−4’−メトキシジベンゾイルメタン、オキシベンゾン及びその誘導体(2−ヒドロキシ−4−メトキシベンゾフェノン、2−ヒドロキシ−4−メトキシベンゾフェノン−5−スルホン酸、2−ヒドロキシ−4−メトキシベンゾフェノン−5−スルホン酸ナトリウム等)、2,4,6,−トリアニリノ−p−(カルボ−2’−エチルヘキシル−1’−オキシ)−1,3,5−トリアジン、フェニルベンズイミダゾールスルホン酸、酸化チタン、微粒子酸化チタン、酸化亜鉛及び微粒子酸化亜鉛、酸化ジルコニウム等が挙げられる。特に酸化チタンや酸化亜鉛等の無機粉体は、微粒子のものを用いるとより高い効果が発揮される。
【0016】
これらの紫外線防止剤のうち、特に好ましいものとしては、パラメトキシケイ皮酸−2−エチルへキシル、4−tert−ブチル−4’−メトキシジベンゾイルメタン、2−ヒドロキシ−4−メトキシベンゾフェノン−5−スルホン酸ナトリウム、酸化チタン、微粒子酸化チタン、酸化亜鉛及び微粒子酸化亜鉛が挙げられる。
【0017】
本実施の形態の皮膚外用剤における紫外線防止剤の配合量としては、好ましくは0.001〜30%、より好ましくは0.01〜25%の範囲である。この範囲であれば蛋白のカルボニル化を抑制する効果が相乗的に発揮され、優れた老化防止効果、保湿効果及び肌荒れ効果を示す皮膚外用剤を得ることができる。
【0018】
本発明の皮膚外用剤の配合形態の例としては、特に限定されず、例えば、乳液、クリーム、化粧水、美容液、パック、洗浄料、メーキャップ化粧料、分散液、軟膏、液剤、エアゾール、貼付剤、パップ剤、リニメント剤等の、いずれの形態の化粧料であっても外用医薬品等であってもよい。
【0019】
又、本発明の皮膚外用剤は、前記エーデルワイス由来成分及び紫外線防止剤以外に、化粧料や医薬部外品、外用医薬品等に通常使用される各種の成分、即ち、水、アルコール、油剤、界面活性剤、増粘剤、粉体、キレート剤、pH調整剤、保湿剤、美白剤、抗炎症剤、細胞賦活剤等の各種薬効剤、動植物・微生物由来の抽出物、香料等を、本発明の効果を損なわない範囲で適宜加えることができる。
【0020】
【実施例】
以下に実施例を挙げて本発明をさらに具体的に説明するが、本発明の範囲は下記の実施例に限定されることはない。
【0021】
[例1:蛋白質のカルボニル化抑制試験]
牛血清アルブミンをSDS及びメルカプトエタノールを含有するトリスバッファーに溶解し、アルブミン溶液を調製した後に、エーデルワイス抽出物(ペンタファーム社製;乾燥固形分7.5%)を最終濃度が0(対照)、1.3、2.5、5%になるように添加した。この混合液に、ベンゾイルペルオキシド溶液を0.1mmol/l加え、過酸化反応を行なって各濃度の試料を調製した。次に、各試料について、インタジェン社のOxyBlot Protein Oxidation Detection Kitを用いてドットブロットを行い、カルボニル基を化学発光により検出し、その強度を対照の強度と比較することにより、カルボニル化抑制率を算出した。結果を下記表1に示す。
なお、本試験では、便宜のために、牛血清アルブミンのカルボニル化抑制率によって評価したが、ケラチン等の真皮、表皮及び角層を構成している蛋白質を対象とした試験でも、同様の結果が得られるものと推定できる。
【0022】
【表1】

Figure 2004107268
【0023】
[例2:ケラチンの水分保持能試験]
6cmシャーレにケラチン(東京化成製)を一定量入れ、例1にも使用したエーデルワイス抽出物(ペンタファーム社製;乾燥固形分7.5%)を、最終濃度が0、2.5、5%になるようケラチンと混合した。次に、ベンゾイルペルオキシド溶液を0及び0.1mM加え、過酸化反応を行ない、一晩減圧乾燥後、重量を測定した。最後に、温度22℃、湿度95%の恒温恒湿器に入れ、1日後の重量を測定した。下記の計算式に基づいてケラチンの抱水能を求めた。結果を下記表2に示す。
【0024】
【数1】
Figure 2004107268
【0025】
但し、式中、Webはエーデルワイス抽出物を混合した後に、過酸化反応を行ったサンプルの水分量の変化、Wvbはベヒクル(グリセリン55%、エチルアルコール45%)を混合した後に、過酸化反応を行ったサンプルの水分量の変化、Wvはベヒクルを混合した後に、過酸化反応を行わなかったケラチンの水分量の変化を示す。
【0026】
表1より、エーデルワイス抽出物は高いカルボニル化抑制効果を示すことが明らかとなった。更に、表2よりエーデルワイス抽出物に明らかな抱水能の上昇が認められた。このことから、エーデルワイス抽出物を肌に適用することにより、カルボニル化が抑制され、保湿効果が発揮されることが期待できる。
【0027】
【表2】
Figure 2004107268
【0028】
[例3:クリーム]
表3に示す組成で、下記製法によりクリームを調製し、エーデルワイス抽出物の保湿性向上効果を下記試験方法により調べた。この結果を下記表3に示す。
(製法)
下記表3に示す成分(1)〜(6)、(8)〜(12)を混合し、加熱して70℃に保った混合物に、成分(14)を加熱して70℃に保った後に加えて乳化した。この乳化物に、成分(7)と(13)を加えた後、冷却してクリームを得た。
【0029】
(試験方法)
被験クリーム1品につき35〜48才の女性6名をパネルとし、毎日朝と夜の2回、14週間にわたって洗顔後に被験クリームの適量を顔面に塗布した。塗布による保湿効果を皮膚水分量(測定機器;SKICON−200[アイ・ビィ・エス社製])及び経表皮水分蒸散量(測定機器;エバポリメーターEP1A[Molndal社製]を測定することにより評価した。保湿能の向上により、皮膚水分量は上昇し、経表皮水分蒸散量は減少する。
【0030】
(組成及び結果)
【表3】
Figure 2004107268
【0031】
表3の結果に示される如く、種々の薬効剤を配合した本発明品1を皮膚に適用することにより、皮膚水分量の上昇及び経表皮水分蒸散量の減少が認められ、保湿効果を有することが認められた。さらに、紫外線防止剤と併用した本発明品2〜5、即ち、パラメトキシケイ皮酸−2−エチルヘキシルを配合した本発明品2、4−tert−ブチル−4’−メトキシベンゾイルメタンを配合した本発明品3、微粒子酸化チタンを配合した本発明品4、微粒子酸化亜鉛を配合した本発明品5は、これらを皮膚に適用することにより、エーデルワイス抽出物を単独で配合したときと比較して皮膚水分量の上昇及び経表皮水分蒸散量の減少が認められた。従って、紫外線防止剤を併用することにより、相乗的な保湿効果の向上が認められた。
【0032】
[例4:洗顔料]
下記成分(1)〜(11)及び(17)を加熱混合し、室温まで冷却した後、(12)〜(16)を添加混合することにより洗顔料を得た。
Figure 2004107268
【0033】例4で調製した洗顔料は、経時安定性に優れ、皮膚に適用することにより、うるおいを皮膚内にとどめ、それによって肌荒れを改善し、うるおいのある美しい肌にする洗顔料であった。
【0034】
[例5:化粧水]
下記成分(1)〜(9)及び(14)、(15)を混合溶解した混合液を、混合溶解した成分(10)〜(13)及び(16)〜(19)の混合物に添加し、混合して化粧水を得た。
Figure 2004107268
【0035】
[例6:化粧水]
下記成分(1)〜(10)を混合溶解した混合液と、成分(11)〜(14)を混合溶解した混合液とを混合して均一にし、化粧水を得た。
Figure 2004107268
【0036】
[例7:乳液]
下記成分(12)〜(16)及び(20)を加熱混合し、70℃に保った混合物に、成分(1)〜(11)を加熱混合し、70℃に保った混合物を加えて混合し、均一に乳化した。この乳化物を冷却後、(17)〜(19)、(21)及び(22)を加え、均一に混合して乳液を得た。
Figure 2004107268
【0037】
例5〜7で得られた各化粧水及び乳液は、いずれも経時安定性に優れ、皮膚に適用することにより、うるおいを皮膚内にとどめることができ、それによって、肌荒れを改善し、つや、張りのある美しい肌にする化粧水及び乳液であった。
【0038】
[例8:軟膏]
下記成分(6)、(7)及び(8)の一部を加熱混合し、75℃に保った混合物を、成分(1)〜(5)を加熱混合し、75℃に保った混合物に徐々に加えた。この混合物を冷却しながら、(8)の残部で溶解した(9)〜(12)を加え、軟膏を得た。
Figure 2004107268
【0039】
例8の軟膏は、経時安定性に優れ、皮膚に適用することにより、肌荒れを改善し、うるおい、つや、張りのある美しい肌にする軟膏であった。
【0040】
[例9:パック]
下記成分(1)〜(7)を混合し、70℃に加熱して溶解した混合物に、成分(8)及び(9)を混合して溶解した混合物を加え、混合した後、冷却して(10)〜(12)を均一に分散してパックを得た。
Figure 2004107268
【0041】例9のパックは、経時安定性に優れ、皮膚に適用することにより、肌荒れを改善し、うるおい、つや、張りのある美しい肌にするパックであった。
【0042】
[例10:リキッドファンデーション]
下記成分(1)〜(7)を加熱し混合溶解した混合物に、成分(13)〜(18)を加え、均一に混合し、70℃に保った。この混合物に、成分(8)〜(12)を均一に溶解し、70℃に保った混合物を添加して、均一に乳化した。この乳化物を冷却後、成分(19)〜(22)を添加してリキッドファンデーションを得た。
Figure 2004107268
【0043】
[例11:油性ファンデーション]
下記成分(1)〜(8)及び(13)〜(17)を80℃で加熱溶解した混合物に、成分(9)〜(12)を加えて均一に混合し、冷却固化して油性ファンデーションを得た。
Figure 2004107268
【0044】
[例12:日焼け止め乳液]
下記成分(1)〜(13)を混合分散した混合物に、成分(14)〜(17)を混合溶解した混合物を添加して、均一に乳化した。この乳化物に、成分(18)〜(20)を添加して日焼け止め乳液を得た。
Figure 2004107268
【0045】
例10〜12は経時安定性に優れ、皮膚に適用することにより、肌荒れを改善し、うるおい感やつや、張りのある美しい肌にする改善するリキッドファンデーション、油性ファンデーション及び日焼け止め乳液であった。
【0046】
【発明の効果】
本発明によれば、蛋白質、特に角質細胞を構成するケラチン等の蛋白質のカルボニル化を抑制し得る蛋白質のカルボニル化抑制剤を提供することができる。また、本発明によれば、皮膚に対する安全性が良好であるとともに、皮膚の保湿性を高める効果を有する皮膚外用剤および方法を提供することができる。[0001]
[Technical field to which the invention belongs]
The present invention relates to a carbonylation inhibitor that suppresses carbonylation of a protein, particularly a protein that constitutes keratinocytes of the skin, and the like, and a skin external preparation and method using the same for improving moisture retention.
[0002]
[Prior art]
The outermost layer of the skin consists of keratinocytes, 85% of which is composed of keratin. Keratin is a fibrous molecule composed of 450 to 500 amino acids, and as it differentiates from the basal layer into the stratum corneum, it fibrillates in cells to form a stratum corneum structure. In recent years, it has been reported that this keratin is carbonylated by oxidative stress (for example, ultraviolet rays, cigarette smoke) or the like that is routinely applied to the skin (see, for example, Non-Patent Document 1). However, there is no report about how the skin is damaged by carbonylation of keratin constituting keratinocytes.
[0003]
On the other hand, since ingredients derived from natural products are safe in the past, emulsions, creams, lotions, cosmetics, packs, cleaning agents, dispersions, ointments, liquids, aerosols, patches, poultices, liniments Are added as various medicinal agents to various external preparations for skin. For example, it has been reported that an extract of Edelweiss has a whitening effect (see, for example, Patent Document 1), and that an extract of Edelweiss is effective as an active oxygen scavenger (see, for example, Patent Document 2). However, there is no description about the relationship with the keratin carbonylation.
[0004]
[Non-Patent Document 1]
Jens J. Thiele et al. Protein Oxidation in Human Stratum Corneum: Susceptibility of Keratins to Oxidation in Vitro and Presence of a Keratine Oxidation Gradient In Vivo. THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 113, no. 3, p. 335, 339 (1999)
[Patent Document 1]
JP 2002-138027 A [Patent Document 2]
Japanese Patent Laid-Open No. 2001-288032
[Problems to be solved by the invention]
An object of the present invention is to provide a protein carbonylation inhibitor capable of suppressing the carbonylation of a protein, particularly a protein such as keratin constituting keratinocytes. Another object of the present invention is to provide an external preparation for skin and a method having an effect of improving the moisture retention of the skin while having good safety to the skin.
[0006]
[Means for Solving the Problems]
As a result of intensive studies on the carbonylation of keratin that constitutes keratinocytes, the present inventors usually have taken in a lot of water molecules, but the carbonylation has eliminated water molecules, It was found that keratin after carbonylation cannot take up water molecules. Furthermore, it has been found that this dries the skin and impairs the appearance of the skin. Furthermore, as a result of further investigation based on this finding, it was found that a component derived from Edelweiss suppresses carbonylation of a protein, and that a skin external preparation containing the component has an effect of enhancing the moisture retention of the skin. The present invention has been completed.
[0007]
As one aspect of the present invention, there is provided a protein carbonylation inhibitor comprising an Edelweiss-derived component as an active ingredient.
Further, as another embodiment of the present invention, a skin external preparation containing an Edelweiss-derived component as a protein carbonylation inhibitor; a moisturizing skin external preparation containing an Edelweiss-derived component as an active ingredient; and further containing an ultraviolet light inhibitor And a method for suppressing protein carbonylation by supplying an Edelweiss-derived component; and a method for improving skin moisture retention by supplying an Edelweiss-derived component.
[0008]
DETAILED DESCRIPTION OF THE INVENTION
The Edelweiss (Leontopodium alpinum) used in the present invention belongs to the genus Leontopodium and is known as a plant symbolizing the European Alps. Since Edelweiss is a very rare alpine plant and its picking is prohibited, it has heretofore been very difficult to obtain as a cosmetic material. The Edelweiss used in the present invention is obtained with formal permission and supplied by cultivation. In the present invention, the production area of Edelweiss is not particularly limited.
[0009]
The preparation of the above-mentioned Edelweiss-derived component is not particularly limited, but examples thereof include whole grass, or roots, stems, shoots, leaves, flowers, seeds and the like from any one or more sites. It can be prepared using a general extraction method. More specifically, after subjecting these to appropriate treatment such as drying, shredding, pressing, or fermentation, they can be extracted by immersing them in a solvent at a low temperature or from room temperature to warming. During the extraction, the solvent may be appropriately stirred or the solvent may be heated. Examples of the solvent to be used include water, lower monohydric alcohols (methyl alcohol, ethyl alcohol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (glycerin, propylene glycol, 1, 3). -Butylene glycol, etc.), lower alkyl esters (ethyl acetate, etc.), hydrocarbons (benzene, hexane, pentane, etc.), ketones (acetone, methyl ethyl ketone, etc.), ethers (diethyl ether, tetrahydrofuran, dipropyl ether, etc.), acetonitrile 1 type, or 2 or more types can be used.
[0010]
The extract obtained by the above method can be used for various uses as a protein carbonylation inhibitor after being left or aged for an appropriate period. If necessary, it can be used after being subjected to a purification treatment such as deodorization and decolorization by filtration or ion exchange resin within a range that does not affect the effect of the present invention. Further, a fraction having high activity can be taken out and used by using a separation means such as liquid chromatography.
[0011]
As an example of a preferable extraction method, using ethyl alcohol having a water content of 0 to 100 vol%, 1,3-butylene glycol or glycerin, extraction is performed at room temperature or after heating for 1 to 5 days, followed by filtration. There is a method in which the obtained filtrate is further left to mature for about one week and then filtered again. In addition, as the component derived from Edelweiss, “Edelweiss GC” (manufactured by Pentafarm) is preferably used.
[0012]
The form of the protein carbonylation inhibitor of the present invention is not particularly limited as long as it contains an Edelweiss-derived component as an active ingredient. It can be used in any form such as liquid, paste or gel. Alternatively, a liquid extract or the like can be dried and solidified, or dried by spray drying or the like and used as a powder.
[0013]
The component derived from Edelweiss functions as a protein carbonylation inhibitor. The carbonylation inhibitor of the present invention is particularly excellent in the effect of suppressing carbonylation of stratum corneum, epidermis and dermis constituting proteins, more specifically keratin, collagen, and elastin among proteins. It is also excellent as an inhibitor of enzyme protein carbonylation. As mentioned above, carbonylation of proteins, especially keratins that make up keratinocytes, reduces the skin's moisturizing properties and causes the appearance of the skin, such as rough skin, moisturized skin, reduced gloss, and so on. Damage. The protein carbonylation inhibitor of the present invention is added to a skin external preparation, and the skin external preparation is applied to the skin to suppress protein, particularly keratin carbonylation, and as a result, the skin moisturizing properties. Can improve the appearance of the skin.
In addition, in this specification, the term “skin moisturizing effect” is an effect that can be directly confirmed by the moisture retention ability test performed in the examples, as well as rough skin due to dry skin, moist feeling of skin, gloss and tension. It shall be interpreted in the broadest sense including the effect of preventing or improving the decline of the above.
[0014]
Hereinafter, the skin external preparation containing the protein carbonylation inhibitor of the present invention will be described.
The external preparation for skin of the present invention is characterized by containing the carbonylation inhibitor. The carbonylation inhibitor in the external preparation for skin of the present invention, that is, the content of the component derived from Edelweiss is preferably 0.00001 to 5% by mass (hereinafter simply referred to as “%”) as a dry solid content, More preferably, it is 0.0001 to 2%. If it exists in this range, this component can be mix | blended stably, and the high carbonylation inhibitory effect and the moisturizing improvement effect based on the effect can be exhibited. Moreover, when using an extract, if the content of the dry solid content which is a solute is in the said range, the extract concentration will not be limited at all.
[0015]
As a preferred embodiment of the present invention, a skin external preparation containing the above-mentioned Edelweiss-derived component and one or two or more kinds of UV inhibitors can be mentioned.
In the present embodiment, as the ultraviolet ray inhibitor used, paramethoxycinnamic acid-2-ethylhexyl, 4-tert-butyl-4′-methoxydibenzoylmethane, oxybenzone and derivatives thereof (2-hydroxy-4-methoxy) Benzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid, sodium 2-hydroxy-4-methoxybenzophenone-5-sulfonate, etc.), 2,4,6, -trianilino-p- (carbo-2'-) Examples thereof include ethylhexyl-1′-oxy) -1,3,5-triazine, phenylbenzimidazolesulfonic acid, titanium oxide, fine particle titanium oxide, zinc oxide, fine particle zinc oxide and zirconium oxide. In particular, inorganic powders such as titanium oxide and zinc oxide are more effective when fine particles are used.
[0016]
Among these UV inhibitors, particularly preferred are 2-methoxyhexyl paramethoxycinnamate, 4-tert-butyl-4′-methoxydibenzoylmethane, 2-hydroxy-4-methoxybenzophenone-5. -Sodium sulfonate, titanium oxide, particulate titanium oxide, zinc oxide and particulate zinc oxide.
[0017]
As a compounding quantity of the ultraviolet inhibitor in the skin external preparation of this Embodiment, Preferably it is 0.001 to 30%, More preferably, it is the range of 0.01 to 25%. If it is this range, the effect which suppresses carbonylation of protein will be exhibited synergistically, and the skin external preparation which shows the outstanding antiaging effect, a moisturizing effect, and the rough skin effect can be obtained.
[0018]
Examples of the formulation of the external preparation for skin of the present invention are not particularly limited. For example, emulsions, creams, lotions, cosmetics, packs, cleaning agents, makeup cosmetics, dispersions, ointments, solutions, aerosols, patches Any form of cosmetics such as pills, poultices, liniments and the like may be external medicines.
[0019]
Further, the external preparation for skin of the present invention includes various components that are usually used in cosmetics, quasi-drugs, external medicines, in addition to the above-mentioned Edelweiss-derived component and UV-protecting agent, that is, water, alcohol, oil agent, interface. Various active agents, thickeners, powders, chelating agents, pH adjusters, moisturizers, whitening agents, anti-inflammatory agents, cell activators, and other medicinal agents, extracts derived from animals, plants and microorganisms, fragrances, etc. As long as the effect is not impaired, it can be added as appropriate.
[0020]
【Example】
The present invention will be described more specifically with reference to the following examples. However, the scope of the present invention is not limited to the following examples.
[0021]
[Example 1: Protein carbonylation inhibition test]
Bovine serum albumin was dissolved in Tris buffer containing SDS and mercaptoethanol to prepare an albumin solution, and then an Edelweiss extract (Pentafarm; dry solid content: 7.5%) was added to a final concentration of 0 (control), 1.3, 2.5, and 5% were added. To this mixed solution, 0.1 mmol / l of benzoyl peroxide solution was added and a peroxidation reaction was performed to prepare samples of various concentrations. Next, for each sample, dot blotting was performed using Ingen's OxyBlot Protein Oxidation Detection Kit, the carbonyl group was detected by chemiluminescence, and the intensity was compared with the intensity of the control. Calculated. The results are shown in Table 1 below.
In this study, for the sake of convenience, the carbonylation inhibition rate of bovine serum albumin was evaluated for the sake of convenience. However, similar results were obtained in a test for keratin and other proteins constituting the dermis, epidermis and stratum corneum. It can be estimated that it will be obtained.
[0022]
[Table 1]
Figure 2004107268
[0023]
[Example 2: Water retention ability test of keratin]
A certain amount of keratin (manufactured by Tokyo Chemical Industry) is put into a 6 cm petri dish, and the edelweiss extract (Pentafarm Co., Ltd .; dry solid content: 7.5%) used in Example 1 is added to a final concentration of 0, 2.5, 5% And mixed with keratin. Next, 0 and 0.1 mM of a benzoyl peroxide solution were added, a peroxidation reaction was performed, and the weight was measured after drying under reduced pressure overnight. Finally, it was placed in a thermo-hygrostat with a temperature of 22 ° C. and a humidity of 95%, and the weight after one day was measured. The ability of keratin to hold water was determined based on the following formula. The results are shown in Table 2 below.
[0024]
[Expression 1]
Figure 2004107268
[0025]
However, in the formula, after mixing the Edelweiss extract, Web is the change in the amount of water in the sample subjected to the peroxidation reaction, and Wvb is the peroxidation reaction after mixing the vehicle (glycerin 55%, ethyl alcohol 45%). The change in water content of the sample performed, Wv, shows the change in the water content of keratin that did not undergo peroxidation after mixing the vehicle.
[0026]
From Table 1, it became clear that an Edelweiss extract shows a high carbonylation inhibitory effect. Furthermore, from Table 2, an apparent increase in water-holding ability was observed in the Edelweiss extract. From this fact, it can be expected that by applying the Edelweiss extract to the skin, carbonylation is suppressed and a moisturizing effect is exhibited.
[0027]
[Table 2]
Figure 2004107268
[0028]
[Example 3: Cream]
With the composition shown in Table 3, a cream was prepared by the following production method, and the moisturizing effect of the Edelweiss extract was examined by the following test method. The results are shown in Table 3 below.
(Manufacturing method)
Components (1) to (6) and (8) to (12) shown in Table 3 below were mixed, heated to a mixture maintained at 70 ° C, and then component (14) was heated and maintained at 70 ° C. In addition, it was emulsified. Components (7) and (13) were added to this emulsion, and then cooled to obtain a cream.
[0029]
(Test method)
A panel of 6 females aged 35 to 48 years per test cream was prepared, and an appropriate amount of the test cream was applied to the face after washing the face twice a morning and night for 14 weeks. Moisturizing effect by application is evaluated by measuring skin moisture content (measuring instrument; SKICON-200 [made by IBS Co., Ltd.]) and transepidermal moisture transpiration (measuring instrument; Evapolymeter EP1A [made by Moldal Co., Ltd.]) By improving the moisture retention capacity, the skin moisture content increases and the transepidermal moisture transpiration rate decreases.
[0030]
(Composition and results)
[Table 3]
Figure 2004107268
[0031]
As shown in the results of Table 3, when the product 1 of the present invention containing various medicinal agents is applied to the skin, an increase in skin water content and a decrease in transepidermal water transpiration are observed and it has a moisturizing effect. Was recognized. In addition, the present invention products 2 to 5 used in combination with an ultraviolet light inhibitor, that is, the present invention product 2 containing 4-methoxyhexyl paramethoxycinnamate, a book containing 4-tert-butyl-4'-methoxybenzoylmethane Inventive product 3, Invented product 4 containing fine particle titanium oxide, and Invented product 5 containing fine particle zinc oxide are applied to the skin, so that the skin is compared with the case where the Edelweiss extract is added alone. An increase in water content and a decrease in transepidermal water transpiration were observed. Accordingly, a synergistic improvement in the moisturizing effect was recognized by using the ultraviolet light inhibitor in combination.
[0032]
[Example 4: Face wash]
The following components (1) to (11) and (17) were heated and mixed, cooled to room temperature, and then (12) to (16) were added and mixed to obtain a face wash.
Figure 2004107268
The face wash prepared in Example 4 has excellent stability over time, and is applied to the skin to keep the moisture in the skin, thereby improving rough skin and making the skin beautiful and moist. It was.
[0034]
[Example 5: lotion]
Add the mixed solution obtained by mixing and dissolving the following components (1) to (9) and (14) and (15) to the mixture of the mixed and dissolved components (10) to (13) and (16) to (19), The lotion was obtained by mixing.
Figure 2004107268
[0035]
[Example 6: lotion]
A mixed solution obtained by mixing and dissolving the following components (1) to (10) and a mixed solution obtained by mixing and dissolving the components (11) to (14) were mixed and made uniform to obtain a lotion.
Figure 2004107268
[0036]
[Example 7: Latex]
The following components (12) to (16) and (20) are heated and mixed, and components (1) to (11) are heated and mixed to a mixture kept at 70 ° C, and the mixture kept at 70 ° C is added and mixed. Emulsified uniformly. After cooling this emulsion, (17) to (19), (21) and (22) were added and mixed uniformly to obtain an emulsion.
Figure 2004107268
[0037]
Each lotion and milky lotion obtained in Examples 5 to 7 are all stable over time, and can be applied to the skin to keep moisture in the skin, thereby improving rough skin, It was a lotion and milky lotion that gave beautiful skin with tension.
[0038]
[Example 8: Ointment]
A part of the following components (6), (7) and (8) were mixed by heating, and the mixture kept at 75 ° C was gradually mixed into the mixture kept at 75 ° C by heating and mixing components (1) to (5). Added to. While this mixture was cooled, (9) to (12) dissolved in the remainder of (8) were added to obtain an ointment.
Figure 2004107268
[0039]
The ointment of Example 8 was an ointment that was excellent in stability over time and applied to the skin to improve rough skin and make it beautiful, moist, glossy, and firm.
[0040]
[Example 9: Pack]
The following components (1) to (7) are mixed, and the mixture in which the components (8) and (9) are dissolved by adding the components (8) and (9) to the mixture dissolved by heating to 70 ° C. is added, mixed, and then cooled ( 10) to (12) were uniformly dispersed to obtain a pack.
Figure 2004107268
The pack of Example 9 was excellent in stability over time, and was applied to the skin to improve rough skin and to make the skin beautiful, moist, glossy and firm.
[0042]
[Example 10: Liquid foundation]
Components (13) to (18) were added to a mixture in which the following components (1) to (7) were heated and mixed and dissolved, mixed uniformly, and kept at 70 ° C. Components (8) to (12) were uniformly dissolved in this mixture, and the mixture maintained at 70 ° C. was added to uniformly emulsify. After cooling this emulsion, components (19) to (22) were added to obtain a liquid foundation.
Figure 2004107268
[0043]
[Example 11: Oily foundation]
Add components (9) to (12) to a mixture in which the following components (1) to (8) and (13) to (17) are heated and dissolved at 80 ° C., mix uniformly, cool and solidify to obtain an oily foundation. Obtained.
Figure 2004107268
[0044]
[Example 12: Sunscreen emulsion]
To the mixture in which the following components (1) to (13) were mixed and dispersed, the mixture in which the components (14) to (17) were mixed and dissolved was added to uniformly emulsify. Components (18) to (20) were added to this emulsion to obtain a sunscreen emulsion.
Figure 2004107268
[0045]
Examples 10 to 12 were liquid foundations, oily foundations, and sunscreen emulsions that were excellent in stability over time and applied to the skin to improve rough skin and improve moist feeling, gloss, and firm skin.
[0046]
【The invention's effect】
ADVANTAGE OF THE INVENTION According to this invention, the protein carbonylation inhibitor which can suppress carbonylation of proteins, especially proteins, such as keratin which comprises a keratinocyte, can be provided. Moreover, according to this invention, while providing the safety | security with respect to skin, the skin external preparation and method which have the effect which improves the moisture retention of skin can be provided.

Claims (6)

エーデルワイス由来の成分を有効成分とする蛋白質のカルボニル化抑制剤。A protein carbonylation inhibitor comprising an Edelweiss-derived ingredient as an active ingredient. エーデルワイス由来の成分を蛋白質のカルボニル化抑制剤として含有する皮膚外用剤。An external preparation for skin containing a component derived from Edelweiss as a protein carbonylation inhibitor. エーデルワイス由来の成分を有効成分として含有する保湿性向上効果を有する皮膚外用剤。A skin external preparation having an effect of improving moisturizing properties, containing an Edelweiss-derived component as an active ingredient. さらに紫外線防止剤を含有する請求項2又は3に記載の皮膚外用剤。Furthermore, the skin external preparation of Claim 2 or 3 containing a ultraviolet-ray preventing agent. エーデルワイス由来の成分を供給することによって、蛋白質のカルボニル化を抑制する方法。A method for suppressing carbonylation of a protein by supplying a component derived from Edelweiss. エーデルワイス由来の成分を供給することによって、皮膚の保湿性を向上させる方法。A method for improving the moisture retention of the skin by supplying a component derived from Edelweiss.
JP2002272826A 2002-09-19 2002-09-19 Protein carbonylation inhibitor, skin external preparation and method Expired - Lifetime JP4608691B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002272826A JP4608691B2 (en) 2002-09-19 2002-09-19 Protein carbonylation inhibitor, skin external preparation and method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002272826A JP4608691B2 (en) 2002-09-19 2002-09-19 Protein carbonylation inhibitor, skin external preparation and method

Publications (2)

Publication Number Publication Date
JP2004107268A true JP2004107268A (en) 2004-04-08
JP4608691B2 JP4608691B2 (en) 2011-01-12

Family

ID=32269748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002272826A Expired - Lifetime JP4608691B2 (en) 2002-09-19 2002-09-19 Protein carbonylation inhibitor, skin external preparation and method

Country Status (1)

Country Link
JP (1) JP4608691B2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008239494A (en) * 2007-03-23 2008-10-09 Naris Cosmetics Co Ltd External preparation for skin
KR101269993B1 (en) * 2011-02-09 2013-05-31 주식회사 후너스바이오 Cosmetic Composition
EP2623094A1 (en) * 2012-02-02 2013-08-07 DSM IP Assets B.V. Use of an edelweiss extract
US9724291B2 (en) 2014-06-24 2017-08-08 Noevir Co., Ltd. External skin preparation
CN113576985A (en) * 2021-09-09 2021-11-02 广东星芮生物科技有限公司 High-permeability water-locking composition, soothing and moisturizing mask liquid and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001288032A (en) * 2000-04-07 2001-10-16 Kanebo Ltd Active oxygen-eliminating agent and skin cosmetic for preventing aging
JP2002138027A (en) * 2000-10-27 2002-05-14 Kose Corp Skin care preparation for external use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001288032A (en) * 2000-04-07 2001-10-16 Kanebo Ltd Active oxygen-eliminating agent and skin cosmetic for preventing aging
JP2002138027A (en) * 2000-10-27 2002-05-14 Kose Corp Skin care preparation for external use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 113, no. 3, JPN4006007295, pages 335 - 339, ISSN: 0000732964 *
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 113, no. 3, JPNX006060686, pages 335 - 339, ISSN: 0000800342 *
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 113, no. 3, JPNX007029739, pages 335 - 339, ISSN: 0000860077 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008239494A (en) * 2007-03-23 2008-10-09 Naris Cosmetics Co Ltd External preparation for skin
KR101269993B1 (en) * 2011-02-09 2013-05-31 주식회사 후너스바이오 Cosmetic Composition
EP2623094A1 (en) * 2012-02-02 2013-08-07 DSM IP Assets B.V. Use of an edelweiss extract
US9724291B2 (en) 2014-06-24 2017-08-08 Noevir Co., Ltd. External skin preparation
CN113576985A (en) * 2021-09-09 2021-11-02 广东星芮生物科技有限公司 High-permeability water-locking composition, soothing and moisturizing mask liquid and preparation method thereof

Also Published As

Publication number Publication date
JP4608691B2 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
KR101746843B1 (en) Use of a polyphenol-rich plant extract as antioxidant in combination with a hydrating or humectant agent
JP4918202B2 (en) Skin composition
JPS60202806A (en) Whitening cosmetic
JP2002020225A (en) Humectant composition
JP2008239545A (en) Elastase deactivator
JP4117773B2 (en) Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent
KR101175803B1 (en) Cosmetic composition SBRC for skincell regeneration and anti-aging
JP4707437B2 (en) Natural moisturizing factor (NMF) component production promoter
JP4594580B2 (en) Protein carbonylation inhibitor, skin external preparation and method
JP4608691B2 (en) Protein carbonylation inhibitor, skin external preparation and method
JP2011195539A (en) Elastase activity inhibitor
KR100753437B1 (en) Nano-liposomal particles containing red ginseng irradiated with saponin, licorice, biotin, copper peptide, cytokine and cosmetics for hair care
JPH10114670A (en) Composition suitable for external use
JP5226200B2 (en) Sulfated glycosaminoglycan production promoter and skin external preparation containing the same
JPH1029927A (en) Antiaging agent
JP2010150173A (en) Skin whitening agent, melanogenesis inhibitor, and skin whitening skin external preparation
JP2009242310A (en) Involucrin production promoter, transglutaminase-1 production promoter, e-cadherin production promoter and skin care preparation for external use for making skin pore inconspicuous
JP2001181170A (en) Skin care preparation
JP2012201615A (en) Elastase activity inhibitor
JP3101090B2 (en) External preparation for skin
JP2002145752A (en) Skin care preparation and composition for skin care preparation
JP3686394B2 (en) Anti-aging agent, Maillard reaction inhibitor, collagenase activity inhibitor and cosmetics for preventing skin aging containing these
JP2011032182A (en) Singlet oxygen quencher, and skin preparation for external use and cosmetic each comprising the same
RU2119790C1 (en) Agent for biological skin rejuvenation
JP2003342156A (en) External preparation for skin for prevention of aging

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050405

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070412

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070417

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20070608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100628

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20100922

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100922

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131022

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4608691

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term